RxDoctor Payments Data

Chinwe Okafor, MD

Internal Medicine · Longview, TXNPI 1184869950

Payments from drug & device makers

$11,868in general payments, 2019–2025

Across 79 payments — averaging $150.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$10K
  • Novo Nordisk$281
  • Lilly USA, LLC$196
  • Merck$181
  • Exact Sciences$103
  • Shield Therapeutics Inc$86
  • plus $542 from 16 others

What the payments were for

  • Food & beverage$1,388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,868 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$33,306
Medicare patients
121
Services billed
326

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$34,070
MounjaroTirzepatide12$18,860
EliquisApixaban14$10,014
Atorvastatin Calcium69$571
Albuterol Sulfate HfaAlbuterol Sulfate20$371
Amlodipine-ValsartanAmlodipine Besylate/Valsartan14$317
Losartan Potassium41$294
Amlodipine Besylate63$283
Gabapentin23$258
Lisinopril30$232
Carvedilol28$222
Escitalopram Oxalate18$216
Donepezil Hcl12$210
Nifedipine ErNifedipine13$202
Pantoprazole Sodium23$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$281$34,07024 claims
Lilly USA, LLCMounjaro$196$18,86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →